Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report sent to investors on Wednesday morning.

Pulse Biosciences Stock Performance

NASDAQ:PLSE opened at $21.40 on Wednesday. The company has a 50-day moving average of $17.31 and a 200-day moving average of $15.77. Pulse Biosciences has a twelve month low of $6.59 and a twelve month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period last year, the company earned ($0.19) earnings per share.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of PLSE. Vanguard Group Inc. boosted its holdings in shares of Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after purchasing an additional 189,227 shares during the period. State Street Corp increased its stake in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after buying an additional 69,696 shares during the period. Geode Capital Management LLC lifted its position in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after buying an additional 33,200 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Pulse Biosciences by 193.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after buying an additional 97,565 shares during the period. Finally, Westside Investment Management Inc. grew its holdings in shares of Pulse Biosciences by 97.8% during the 2nd quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after acquiring an additional 31,440 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.